Sfoglia per Autore
ALS patients and caregivers communication preferences and information seeking behaviour
2008-01-01 CHIÒ A; MONTUSCHI A; CAMMAROSANO S; DE MERCANTI S; CAVALLO E; ILARDI A; GHIGLIONE P; MUTANI R; CALVO A.
A case of Hyperekplexia with positive anti GlyR antibodies: PERM syndrome
2009-01-01 Giulia Contessa; Stefania De Mercanti; Lorenza Delfico; Rossella Sciolla; mario Coletti Moja; Bruno Ferrero; Cinzia Ferrero; Paolo Ripellino; Emanuela Viglietta; Delon La Puma; Luca Durelli
Spinal Cord Compression due to extramedullary hematopoiesis in a young patient affected by beta thalassemia
2009-01-01 Stefania De Mercanti; Giulia Contessa; lorenza Delfico; Marinella Clerico; Delon La Puma; Emanuela Viglietta; Bruno Ferrero; Marco Iudicello; Rossella Sciolla; Luca Durelli
Neutralizing antibodies in multiple sclerosis patients treated with 375 μg interferon-β-1b
2009-01-01 Durelli L; Barbero P; Cucci A; Ferrero B; Ricci A; Contessa G; De Mercanti S; Ripellino P; Lapuma D; Viglietta E; Bergui M; Versino E; Clerico M; OPTIMS Trial NAb Sub-Study Group
can the increase of T-helper 17 Lymphocyte percentage in peripheral blood anticipate a relapse in relapsing remitting multiple sclerosis?
2010-01-01 Luca Durelli; Marinella Clerico; Simona Rolla; Giulia Contessa; Stefania De Mercanti; Antoni Uccelli; Mauro Zaffaroni; Paola Cavalla; Luciano Rinaldi; Cristoforo Comi; Roberto Cavallo; Luisa Sosso; Francesco Novelli
PRO-INFLAMMATORY CYTOKINE AND CHEMOKINE MRNA BLOOD LEVEL IN MULTIPLE SCLEROSIS IS RELATED TO TREATMENT RESPONSE AND INTERFERON-BETA DOSE
2010-01-01 Cucci A; Barbero P; Clerico M; Ferrero B; Versino E; Contessa G; Demercanti S; Viglietta E; Di Liberto A; Vai AG; Durelli L
T-helper (Th) 22, a newly identified lymphocyte subset, increases 1-3 months before an MS relapse and it is not sensitive to INF beta
2011-01-01 Durelli, L.; Clerico, M.; Rolla, S.; Contessa, G.; De Mercanti, S.; Cucci, A.; Novelli, F.
T-Helper (Th)22, a Newly Identified Lymphocyte Subset, Increases 1-3 Months before an MS Relapse and It Is Not Sensitive to IFN beta
2011-01-01 Durelli L; Clerico M; Rolla S; Contessa G; De Mercanti Stefania; Cucci Angele; Bardina Valentina; Di Liberto Alessandra; Uccelli Antonio; Zaffaroni Mauro; Cavalla P; Rinaldi Luciano; Comi Cristoforo; Sosso Luisa; Cavallo Roberto; Quaglino P; Novelli Franco.
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials
2012-01-01 De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L.
T Regulatories (Tregs) and suppressor cytokine mRNA (IL-10, TGF-beta, IL-27) increase after Alemtuzumab in MS: First 25 Month Immunological Report on 323 and 324 Genzyme trials
2012-01-01 De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Kovarova,I.; Clerico, M.; Durelli, L.
Management of multiple sclerosis patients after the 24th Natalizumab course: the Ty-STOP study
2013-01-01 Clerico M; De Mercanti S; Versino E; Piazza F; Gned D; Brescia Morra V; Lanzillo R; Amato R; Quarantelli M; Ghezzi A; Bianchi A; Baroncini D; Salemi G; Realmuto S; Ferro MT; Vitetta F; Donghia M; Paolicelli D; Trojano M; Durelli L
Natalizumab discontinuation after the 24th course: which is the way? The TY-STOP study
2013-01-01 Clerico M; De Mercanti S; Piazza F; Gned D; Brescia Morra V; Lanzillo R; Amato L; Quarantelli M; Ghezzi A; Bianchi A; Baroncini D; Gibbin M; Vargas J; Salemi G; Realmuto S; Ferro MT; Vitetta F; Sola P; Paolicelli D; Trojano M; Durelli L
Atypical presentation of superficial sclerosis successfully treated with iron chelation
2013-01-01 De Mercanti S; Iudicello M; Clerico M; Piazza F; Gibbin M; Longo F; Durelli L
Role of Th22 expansion in multiple sclerosis disease activity
2013-01-01 De Mercanti S; Clerico M; Rolla S; Bardina V; Quaglino P; De Palma R; Gned D; Novelli F; Durelli L
Treg Cell Function and Related Cytokines and Chemokines Changes during Alemtuzumab Treatment: a 24 Months Immunological Study
2013-01-01 De Mercanti S; Clerico M; Rolla S; Cucci A; Novelli F; Taverna D; Bardina V; Piazza F; Gibbin M; Vargas J; Vladic A; Habek M; Adamec B; Brinar V; Cocco E; Frau J; Annovazzi P; Horakova D; Kovarova I; Durelli L
How to treat MS patients after the 24th natalizumab administration: the TY-STOP trial
2014-01-01 Durelli, L.; De Mercanti, S.F.; Sormani, M.P.; Piazza, F.; Schiavetti, I.; Gned, D.; Brescia Morra, V.; Lanzillo, R.; Amato, L.; Quarantelli, M.; Ghezzi, A.; Bianchi, A.; Baroncini, D.; Salemi, G.; Realmuto, S.; Ferrò, M.T.; Vitetta, F.; Superti, G.; Cavalla, P.; D’Onghia, M.; Paolicelli, D.; Pinessi, L.; Trojano, M.; Clerico, M.
Epigenetic Therapy for Friedreich’s Ataxia: A Phase I Clinical Trial
2014-01-01 Jacoby, D.; Rusche, J.; Iudicello, M.; De Mercanti, S.; Clerico, M; Gibbin, M.; Longo, F.; Miao, W.; Rai, M.; Piga, A.; Pandolfo, M.; Durelli, L.
Heterozygous deletion of KLHL1/ATXN8OS at the SCA8 locus are likely not associated with cerebellar impairment in humans
2014-01-01 G. Mandrile; E. Di Gregorio; H. Goel; D. F. Giachino; S. De Mercanti; M. Iudicello; S. Losa; M. Rolando; L. Ranum; M. De Marchi; A. Brusco
Treatment of multiple sclerosis patients after 24 Natalizumab doses: a prospective observational study: the TY-STOP
2014-01-01 Clerico, M; Schiavetti, I; De Mercanti, Sf; Piazza, F; Gned, D; Brescia Morra, V; Lanzillo, R; Ghezzi, A; Bianchi, A; Salemi, G; Realmuto, S; Sola, P; Vitetta, F; Cavalla, P; Superti, G; Ferraro, D; Paolicelli, D; Trojano, M; Sormani, Mp; Durelli, L
How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study
2014-01-01 S De Mercanti ; M Clerico ; S Rolla ; V Bardina ; M.A Cucci ; D Taverna ; D Cimino ; F Piazza ; E Virgilio ; D Armocida ; M Basso ; A Vladic ; M Habek ; I Adamec ; V Brinar ; E Cocco ; J Frau ; P Annovazzi ; D Horàkovà ; I Kovàrovà ; F Novelli ; L Durelli
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| ALS patients and caregivers communication preferences and information seeking behaviour | 2008 | CHIÒ A; MONTUSCHI A; CAMMAROSANO S; DE MERCANTI S; CAVALLO E; ILARDI A; GHIGLIONE P; MUTANI R; CALVO A. | |
| A case of Hyperekplexia with positive anti GlyR antibodies: PERM syndrome | 2009 | Giulia Contessa; Stefania De Mercanti; Lorenza Delfico; Rossella Sciolla; mario Coletti Moja; Bruno Ferrero; Cinzia Ferrero; Paolo Ripellino; Emanuela Viglietta; Delon La Puma; Luca Durelli | |
| Spinal Cord Compression due to extramedullary hematopoiesis in a young patient affected by beta thalassemia | 2009 | Stefania De Mercanti; Giulia Contessa; lorenza Delfico; Marinella Clerico; Delon La Puma; Emanuela Viglietta; Bruno Ferrero; Marco Iudicello; Rossella Sciolla; Luca Durelli | |
| Neutralizing antibodies in multiple sclerosis patients treated with 375 μg interferon-β-1b | 2009 | Durelli L; Barbero P; Cucci A; Ferrero B; Ricci A; Contessa G; De Mercanti S; Ripellino P; Lapuma D; Viglietta E; Bergui M; Versino E; Clerico M; OPTIMS Trial NAb Sub-Study Group | |
| can the increase of T-helper 17 Lymphocyte percentage in peripheral blood anticipate a relapse in relapsing remitting multiple sclerosis? | 2010 | Luca Durelli; Marinella Clerico; Simona Rolla; Giulia Contessa; Stefania De Mercanti; Antoni Uccelli; Mauro Zaffaroni; Paola Cavalla; Luciano Rinaldi; Cristoforo Comi; Roberto Cavallo; Luisa Sosso; Francesco Novelli | |
| PRO-INFLAMMATORY CYTOKINE AND CHEMOKINE MRNA BLOOD LEVEL IN MULTIPLE SCLEROSIS IS RELATED TO TREATMENT RESPONSE AND INTERFERON-BETA DOSE | 2010 | Cucci A; Barbero P; Clerico M; Ferrero B; Versino E; Contessa G; Demercanti S; Viglietta E; Di Liberto A; Vai AG; Durelli L | |
| T-helper (Th) 22, a newly identified lymphocyte subset, increases 1-3 months before an MS relapse and it is not sensitive to INF beta | 2011 | Durelli, L.; Clerico, M.; Rolla, S.; Contessa, G.; De Mercanti, S.; Cucci, A.; Novelli, F. | |
| T-Helper (Th)22, a Newly Identified Lymphocyte Subset, Increases 1-3 Months before an MS Relapse and It Is Not Sensitive to IFN beta | 2011 | Durelli L; Clerico M; Rolla S; Contessa G; De Mercanti Stefania; Cucci Angele; Bardina Valentina; Di Liberto Alessandra; Uccelli Antonio; Zaffaroni Mauro; Cavalla P; Rinaldi Luciano; Comi Cristoforo; Sosso Luisa; Cavallo Roberto; Quaglino P; Novelli Franco. | |
| Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials | 2012 | De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L. | |
| T Regulatories (Tregs) and suppressor cytokine mRNA (IL-10, TGF-beta, IL-27) increase after Alemtuzumab in MS: First 25 Month Immunological Report on 323 and 324 Genzyme trials | 2012 | De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Kovarova,I.; Clerico, M.; Durelli, L. | |
| Management of multiple sclerosis patients after the 24th Natalizumab course: the Ty-STOP study | 2013 | Clerico M; De Mercanti S; Versino E; Piazza F; Gned D; Brescia Morra V; Lanzillo R; Amato R; Quarantelli M; Ghezzi A; Bianchi A; Baroncini D; Salemi G; Realmuto S; Ferro MT; Vitetta F; Donghia M; Paolicelli D; Trojano M; Durelli L | |
| Natalizumab discontinuation after the 24th course: which is the way? The TY-STOP study | 2013 | Clerico M; De Mercanti S; Piazza F; Gned D; Brescia Morra V; Lanzillo R; Amato L; Quarantelli M; Ghezzi A; Bianchi A; Baroncini D; Gibbin M; Vargas J; Salemi G; Realmuto S; Ferro MT; Vitetta F; Sola P; Paolicelli D; Trojano M; Durelli L | |
| Atypical presentation of superficial sclerosis successfully treated with iron chelation | 2013 | De Mercanti S; Iudicello M; Clerico M; Piazza F; Gibbin M; Longo F; Durelli L | |
| Role of Th22 expansion in multiple sclerosis disease activity | 2013 | De Mercanti S; Clerico M; Rolla S; Bardina V; Quaglino P; De Palma R; Gned D; Novelli F; Durelli L | |
| Treg Cell Function and Related Cytokines and Chemokines Changes during Alemtuzumab Treatment: a 24 Months Immunological Study | 2013 | De Mercanti S; Clerico M; Rolla S; Cucci A; Novelli F; Taverna D; Bardina V; Piazza F; Gibbin M; Vargas J; Vladic A; Habek M; Adamec B; Brinar V; Cocco E; Frau J; Annovazzi P; Horakova D; Kovarova I; Durelli L | |
| How to treat MS patients after the 24th natalizumab administration: the TY-STOP trial | 2014 | Durelli, L.; De Mercanti, S.F.; Sormani, M.P.; Piazza, F.; Schiavetti, I.; Gned, D.; Brescia Morra, V.; Lanzillo, R.; Amato, L.; Quarantelli, M.; Ghezzi, A.; Bianchi, A.; Baroncini, D.; Salemi, G.; Realmuto, S.; Ferrò, M.T.; Vitetta, F.; Superti, G.; Cavalla, P.; D’Onghia, M.; Paolicelli, D.; Pinessi, L.; Trojano, M.; Clerico, M. | |
| Epigenetic Therapy for Friedreich’s Ataxia: A Phase I Clinical Trial | 2014 | Jacoby, D.; Rusche, J.; Iudicello, M.; De Mercanti, S.; Clerico, M; Gibbin, M.; Longo, F.; Miao, W.; Rai, M.; Piga, A.; Pandolfo, M.; Durelli, L. | |
| Heterozygous deletion of KLHL1/ATXN8OS at the SCA8 locus are likely not associated with cerebellar impairment in humans | 2014 | G. Mandrile; E. Di Gregorio; H. Goel; D. F. Giachino; S. De Mercanti; M. Iudicello; S. Losa; M. Rolando; L. Ranum; M. De Marchi; A. Brusco | |
| Treatment of multiple sclerosis patients after 24 Natalizumab doses: a prospective observational study: the TY-STOP | 2014 | Clerico, M; Schiavetti, I; De Mercanti, Sf; Piazza, F; Gned, D; Brescia Morra, V; Lanzillo, R; Ghezzi, A; Bianchi, A; Salemi, G; Realmuto, S; Sola, P; Vitetta, F; Cavalla, P; Superti, G; Ferraro, D; Paolicelli, D; Trojano, M; Sormani, Mp; Durelli, L | |
| How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study | 2014 | S De Mercanti ; M Clerico ; S Rolla ; V Bardina ; M.A Cucci ; D Taverna ; D Cimino ; F Piazza ; E Virgilio ; D Armocida ; M Basso ; A Vladic ; M Habek ; I Adamec ; V Brinar ; E Cocco ; J Frau ; P Annovazzi ; D Horàkovà ; I Kovàrovà ; F Novelli ; L Durelli |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile